Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review (vol 13, pg 1571, 2024)

被引：0
|
作者：
Blumenfeld, Andrew M. [1 ,2 ]
Mechtler, Laszlo [3 ]
Cook, Lisa [1 ]
Rhyne, Christopher [4 ]
Jenkins, Brian [5 ]
Hughes, Olivia [6 ]
Dabruzzo, Brett [7 ]
Manack Adams, Aubrey [7 ]
Diamond, Merle [8 ]
机构：
[1] Los Angeles Headache Ctr, Los Angeles, CA 90067 USA
[2] San Diego Headache Ctr, San Diego, CA 92111 USA
[3] Dent Neurol Inst, Buffalo, NY USA
[4] Norton Neurosci Inst, Louisville, KY USA
[5] Neurosci Grp, Neenah, WI USA
[6] ICON Plc, Blue Bell, PA USA
[7] AbbVie, N Chicago, IL USA
[8] Diamond Headache Clin Ltd, Chicago, IL USA
来源：
PAIN AND THERAPY | 2025年 / 14卷 / 01期
关键词：
D O I：
10.1007/s40122-024-00692-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：441 / 444
页数：4
相关论文
共 50 条
  • [31] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, A. Manack
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1) : 104 - 105
  • [32] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, A. Manack
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 155 - 155
  • [33] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Dikmen, Pinar Yalinay
    Kosak, Seda
    Aydinlar, Elif Ilgaz
    Kocaman, Ayse Sagduyu
    ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
  • [34] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Pınar Yalinay Dikmen
    Seda Kosak
    Elif Ilgaz Aydinlar
    Ayse Sagduyu Kocaman
    Acta Neurologica Belgica, 2018, 118 : 475 - 484
  • [35] A Retrospective United Kingdom Chart Review of Early Vedolizumab Experience: Real-World Treatment, Effectiveness and Safety in Inflammatory Bowel Disease (REVIVE)
    Cummings, Fraser
    Gaya, Daniel
    Irving, Peter
    Subramanian, Sreedhar
    Glen, Fiona
    Frere-Scott, Lucinda
    Demuth, Dirk
    Rathmell, Anna
    Owen, Glynn
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S25 - S26
  • [36] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Grazzi, Licia
    Giossi, Riccardo
    Montisano, Danilo Antonio
    Canella, Mattia
    Marcosano, Marilena
    Altamura, Claudia
    Vernieri, Fabrizio
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01)
  • [37] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Licia Grazzi
    Riccardo Giossi
    Danilo Antonio Montisano
    Mattia Canella
    Marilena Marcosano
    Claudia Altamura
    Fabrizio Vernieri
    The Journal of Headache and Pain, 25
  • [38] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Yedigarova, Larisa
    Adams, Aubrey Manack
    NEUROLOGY, 2021, 96 (15)
  • [39] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine Patients Initially Treated With OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    TOXICON, 2024, 237 : 22 - 22
  • [40] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine (CM) Patients Initially Treated with OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    NEUROLOGY, 2023, 100 (17)
12345